Shares in Actelion Pharmaceuticals Ltd. dropped by almost 8 percent Monday on news that clazosentan failed to reach the primary endpoint in a Phase III pivotal trial in patients who had undergone surgical clipping to treat a form of stroke called aneurysmal subarachnoid hemorrhage (aSAH). (BioWorld International) Read More
